Last updated: July 12, 2026
What claims were at issue in Horizon Pharma Ireland Limited v. Actavis Laboratories UT, Inc. (1:14-cv-07992)?
Answer: The docket identifies a patent dispute tied to an FDA generic entry challenged via a Paragraph IV notice, brought in the U.S. District Court for the District of [court specified in docket caption]. The litigation posture is consistent with an Orange Book patent infringement case under the Hatch-Waxman framework, where Horizon alleged that Actavis’s proposed generic would infringe one or more listed patents.
When was Horizon Pharma Ireland Limited v. Actavis Laboratories UT, Inc. filed and how did the procedural timeline run?
Answer: The action number 1:14-cv-07992 indicates a 2014 filing. The case is a federal patent litigation matter in the U.S. District Court track used for Hatch-Waxman “patent infringement” suits.
Key procedural milestones to extract from the docket
- Case filing (2014): 1:14-cv-07992 filed after an FDA-related generic regulatory event and a Paragraph IV notice cycle.
- Teed-up infringement issues: claim charts and infringement contentions typically follow Rule 16 scheduling and patent case orders.
- Outcome class: the litigation record in these cases commonly ends in one of three ways: stipulated judgment after settlement, dismissal for non-infringement/non-coverage, or summary judgment after claim construction.
(The exact dates of claim construction, Markman orders, dispositive motions, and final judgment must be taken from the docket entries. No entry-level docket facts are present in the prompt.)
What patents protect the drug in dispute and how many were asserted?
Answer: Patent-by-patent identification of the asserted Orange Book listings is required to perform a complete analysis (number of patents, expiration dates, asserted claims, and coverage rationale). The docket caption alone does not include the Orange Book patent list or the asserted patent numbers.
What an actionable patent list should include
- Orange Book patents asserted (U.S. patent numbers)
- Type of patent (composition, formulation, method-of-use, manufacturing)
- Expiration dates and any pediatric exclusivity adjustments
- Terminal disclaimer status
- Claim scope relevant to the generic dosage form and route
(Asserted patent numbers and types are not provided in the prompt.)
What does Horizon allege Actavis infringed under Paragraph IV?
Answer: Under Hatch-Waxman, Horizon’s complaint typically alleges that Actavis’s ANDA product infringes one or more claims of the Orange Book patents that Horizon listed for the reference drug.
How infringement is usually framed in these cases
- Literal infringement theories based on the generic’s labeled composition and manufacturing specs
- Doctrine of equivalents in the alternative for claim limitations argued as substituted or insubstantially changed
- Induced or contributory infringement depending on proposed commercial activity
(The prompt does not specify the asserted claim terms or the infringement theory details.)
What defenses does Actavis typically raise in Hatch-Waxman patent cases like 1:14-cv-07992?
Answer: Typical Actavis defenses in Paragraph IV suits include invalidity and non-infringement defenses, plus statutory defenses tied to claim scope and enablement.
Defense categories that drive outcomes
- Non-infringement: generic formulation or method does not meet claim limitations
- Invalidity: anticipation/obviousness, lack of written description, inadequate enablement, indefiniteness
- Statutory subject matter: less common for pharmaceuticals in this posture, but can be raised depending on patent history and claim framing
- Prosecution history estoppel: limits equivalents after narrowing amendments
(No defense list from the docket is provided in the prompt.)
How strong is the patent estate asserted by Horizon, and what does claim construction suggest about risk?
Answer: A strength assessment must map (1) claim breadth, (2) relevant prior art landscape, (3) how construe orders narrow limitation coverage, and (4) validity risk.
Claim construction analysis that matters
- Whether Markman rulings narrow key limitations (e.g., drug substance identity, particle characteristics, dose regimen, or excipient/formulation constraints)
- Whether construed terms align with Actavis’s planned formulation specs
(No Markman/claim construction content is provided in the prompt.)
What was the litigation outcome: settlement, dismissal, or judgment?
Answer: The docket outcome cannot be stated from the prompt alone. A complete litigation summary requires final disposition, including:
- settlement agreement date and terms that affect launch timing (often a covenant not to sue or reverse-payment structure),
- consent judgment entries,
- dismissal without prejudice/with prejudice,
- or a jury/bench judgment and associated findings.
(No disposition entry is provided in the prompt.)
Did the case include a Paragraph IV settlement that affects generic launch timing?
Answer: Settlement-driven Hatch-Waxman cases commonly include:
- agreed launch dates,
- partial or full carve-outs to allow generic entry after a specified date,
- covenants not to sue,
- and sometimes licensing terms.
No settlement terms or court orders are included in the prompt.
What is the Orange Book status of the involved Horizon product and what is exclusivity exposure?
Answer: Orange Book status requires the reference drug name, ANDA number, and the specific listed patents. The prompt provides only the party caption and case number.
A complete exclusivity exposure view must include:
- listed patents (Orange Book),
- expiration dates and regulatory exclusivities (NCE, pediatric, orphan, method-of-use exclusivity where applicable),
- and the relationship between Orange Book exclusivities and patent expiry.
(Reference product and Orange Book listing data are not provided.)
Which companies were involved beyond Horizon and Actavis, and what is the competitive landscape impact?
Answer: Without docket party list detail (e.g., other defendants, real parties in interest, ANDA labeler or manufacturing entities, and any co-defendants), the competitive impact cannot be correctly allocated.
Biosimilar or generic risk: is this a biologic dispute or a small-molecule ANDA?
Answer: The caption indicates a corporate defendant structure consistent with small-molecule generic litigation. A definitive classification (ANDA vs BLA pathway, biosimilar vs generic) requires the reference product and the FDA approval pathway, which are not provided.
How does this case compare with other Hatch-Waxman litigations involving Actavis defendants?
Answer: Comparative analysis requires:
- the specific reference product(s) involved across cases,
- outcome patterns,
- and Actavis’s typical patent challenge strategy for that chemical class.
The prompt does not include the product identity or adjacent cases.
Commercial impact: what revenue is at risk for Actavis and what damages exposure faces Actavis in 1:14-cv-07992?
Answer: Revenue and damages exposure depends on:
- the reference drug’s U.S. sales,
- the number and strength of asserted patents,
- and the settlement or judgment structure.
None of these are provided.
Key Takeaways
- 1:14-cv-07992 is a 2014 federal Hatch-Waxman style patent litigation between Horizon Pharma Ireland Limited and Actavis Laboratories UT, Inc.
- A full, business-grade litigation summary requires the asserted Orange Book patents, drug identity, docket disposition, and settlement or judgment terms.
- The prompt does not include the necessary docket-level facts to state patent numbers, claim scope, validity determinations, or launch/settlement timing.
FAQs
- What is the fastest way to confirm the asserted Orange Book patents in 1:14-cv-07992?
- Does a Paragraph IV settlement in this case imply a launch-date covenant or a license?
- How do Markman claim construction outcomes typically change infringement risk in formulation patent cases?
- What damages framework applies if Actavis launches “at risk” during an injunction gap?
- How should investors read a docket disposition when the order is not a merits decision?
References
(No citable sources were provided in the prompt.)
